MTX 212
Alternative Names: MTX-212Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Undisclosed Company
- Developer Biodexa Pharmaceuticals; Undisclosed Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Unspecified in United Kingdom (Parenteral, Controlled release)
- 14 Sep 2020 Early research in Unspecified in United Kingdom (Parenteral,Controlled release) before September 2020
- 30 Jun 2020 Midatech has patent protection for Q-Sphera™ microsphere technology before June 2020